name nAnno nOverlap fc zscore pvalue adjp or CIl CIu
path:hsa04360 Axon guidance 175 8 6.46 6.18 2.6e-05 0.0021 7.89 3.14 17.5
path:hsa04370 VEGF signaling pathway 59 4 9.58 5.59 0.00075 0.012 11.1 2.79 32
path:hsa04666 Fc gamma R-mediated phagocytosis 90 5 7.85 5.53 4e-04 0.012 9.11 2.75 23.8
path:hsa04933 AGE-RAGE signaling pathway in diabetic complications 99 5 7.14 5.19 0.00062 0.012 8.23 2.49 21.4
path:hsa05231 Choline metabolism in cancer 99 5 7.14 5.19 0.00062 0.012 8.23 2.49 21.4
path:hsa04668 TNF signaling pathway 108 5 6.54 4.9 0.00092 0.012 7.5 2.27 19.5
path:hsa04662 B cell receptor signaling pathway 70 4 8.08 5.02 0.0014 0.016 9.19 2.33 26.4
path:hsa04380 Osteoclast differentiation 127 5 5.57 4.38 0.0019 0.019 6.31 1.92 16.3
path:hsa04144 Endocytosis 260 7 3.81 3.9 0.0021 0.019 4.39 1.64 10
path:hsa05222 Small cell lung cancer 84 4 6.73 4.46 0.0028 0.022 7.57 1.93 21.6
path:hsa04211 Longevity regulating pathway 89 4 6.35 4.29 0.0035 0.024 7.12 1.82 20.2
path:hsa04810 Regulation of actin cytoskeleton 212 6 4 3.75 0.0035 0.024 4.54 1.56 10.9
path:hsa04930 Type II diabetes mellitus 46 3 9.22 4.72 0.0041 0.025 10.4 1.99 34.4
path:hsa05213 Endometrial cancer 50 3 8.48 4.48 0.0052 0.027 9.49 1.82 31.3
path:hsa04915 Estrogen signaling pathway 98 4 5.77 4.02 0.0049 0.027 6.43 1.64 18.2
path:hsa04660 T cell receptor signaling pathway 103 4 5.49 3.88 0.0058 0.027 6.1 1.56 17.3
path:hsa04022 cGMP-PKG signaling pathway 163 5 4.34 3.64 0.0056 0.027 4.85 1.48 12.5
path:hsa05221 Acute myeloid leukemia 55 3 7.71 4.22 0.0067 0.03 8.57 1.65 28.1
path:hsa05223 Non-small cell lung cancer 58 3 7.31 4.07 0.0078 0.031 8.1 1.56 26.5
path:hsa05210 Colorectal cancer 60 3 7.07 3.99 0.0086 0.031 7.82 1.51 25.5
path:hsa05212 Pancreatic cancer 64 3 6.63 3.82 0.01 0.031 7.3 1.41 23.8
path:hsa05214 Glioma 64 3 6.63 3.82 0.01 0.031 7.3 1.41 23.8
path:hsa05131 Shigellosis 65 3 6.52 3.78 0.011 0.031 7.18 1.39 23.4
path:hsa05211 Renal cell carcinoma 65 3 6.52 3.78 0.011 0.031 7.18 1.39 23.4
path:hsa05230 Central carbon metabolism in cancer 65 3 6.52 3.78 0.011 0.031 7.18 1.39 23.4
path:hsa04664 Fc epsilon RI signaling pathway 67 3 6.33 3.7 0.012 0.031 6.95 1.35 22.6
path:hsa05218 Melanoma 69 3 6.15 3.63 0.013 0.031 6.74 1.31 21.9
path:hsa04724 Glutamatergic synapse 114 4 4.96 3.6 0.0083 0.031 5.48 1.41 15.5
path:hsa04917 Prolactin signaling pathway 70 3 6.06 3.59 0.013 0.031 6.64 1.29 21.5
path:hsa05220 Chronic myeloid leukemia 71 3 5.97 3.56 0.014 0.031 6.54 1.27 21.2
path:hsa04520 Adherens junction 72 3 5.89 3.52 0.014 0.031 6.45 1.25 20.9
path:hsa04071 Sphingolipid signaling pathway 118 4 4.79 3.51 0.0094 0.031 5.29 1.36 14.9
path:hsa04611 Platelet activation 123 4 4.6 3.4 0.011 0.031 5.06 1.3 14.3
path:hsa04068 FoxO signaling pathway 131 4 4.32 3.24 0.013 0.031 4.74 1.22 13.3
path:hsa04510 Focal adhesion 199 5 3.55 3.08 0.013 0.031 3.93 1.2 10.1
path:hsa05203 Viral carcinogenesis 201 5 3.52 3.06 0.013 0.031 3.89 1.19 9.96
path:hsa01524 Platinum drug resistance 73 3 5.81 3.49 0.015 0.032 6.35 1.23 20.6
path:hsa04910 Insulin signaling pathway 138 4 4.1 3.1 0.016 0.034 4.48 1.15 12.6
path:hsa01521 EGFR tyrosine kinase inhibitor resistance 79 3 5.37 3.3 0.018 0.037 5.85 1.14 18.9
path:hsa05161 Hepatitis B 144 4 3.93 3 0.018 0.037 4.29 1.1 12
path:hsa04072 Phospholipase D signaling pathway 145 4 3.9 2.98 0.019 0.037 4.26 1.1 12
path:hsa04012 ErbB signaling pathway 86 3 4.93 3.1 0.023 0.043 5.35 1.04 17.2
path:hsa05215 Prostate cancer 87 3 4.87 3.07 0.023 0.043 5.28 1.03 17
